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Abstract
 Background—While previous studies find no evidence of an association between opioid use 
and intimate partner violence perpetration among community samples, initial evidence has 
detected increased rates of partner violence among individuals receiving pharmacological 
intervention for opioid dependence.
 Objective—The current study evaluated the role of current comorbid substance use diagnoses, 
a robust risk factor for violent behavior, on the likelihood of perpetrating partner violence among a 
high risk sample of offenders receiving pharmacological intervention for opioid dependence.
 Method—We analyzed self-report data provided by 81 (55 male) opioid dependent offenders 
during a court-ordered substance use interview.
 Results—Approximately one third of the sample evidenced the recent use of intimate partner 
violence. Findings indicated that cocaine and benzodiazepine use were independently associated 
with an increased likelihood of reporting physical partner violence. Alcohol and cannabis use were 
not associated with partner violence.
 Conclusions—The current results offer further support for the ongoing need to conduct 
routine partner violence screenings among substance involved offenders and highlight the 
importance of developing individualized treatment plans that address comorbid substance use and 
partner violent behaviors among individuals in treatment for opioid dependence.
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Although it is generally recognized that substance use represents a robust risk factor for the 
perpetration of physical intimate partner violence (IPV), our understanding of the 
relationship between opioid dependence and IPV remains obscured by mixed findings 
among a limited number of investigations. A meta-analytic review of six studies revealed a 
very small cumulative relationship between opioid use and physical IPV perpetration among 
males (d = .16, 95% CI = .05-.27).1 These findings were largely supported by an analysis of 
nationally representative data collected from a sample of 25,778 non-institutionalized adults 
in the United States who provided data in Wave 2 of the National Epidemiologic Study on 
Alcohol and Related Conditions.2 Prior research suggests that rates of IPV are elevated 
among offender samples with previously incarcerated males being four times more likely to 
perpetrate IPV than non-incarcerated males.3 Clinical samples and judicially mandated 
treatment seeking offenders represent equally salient groups with consistent evidence 
indicating that between one third and one half of participants in relevant samples have 
perpetrated recent acts of IPV.4,5 In one sample of female offenders, daily opioid use was not 
associated with general physical IPV.6 However, researchers recently found stronger effects 
among men receiving pharmacological intervention to treat opioid dependence, reporting 
greater past year physical IPV perpetration among the treatment sample than community 
controls.7 Another study found that men receiving pharmacological treatment for opioid 
dependence also demonstrated significantly greater aggression during laboratory analogue 
paradigms than men in a healthy comparison group.8 Together, these findings suggest that 
the issue of severity may factor into the association between opioid use and IPV with the 
strongest effects emerging among dependent individuals and those who qualify for 
pharmacological intervention. The current study was undertaken to evaluate the association 
between co-occurring substance use disorders and IPV among a high-risk, clinical sample of 
offenders receiving pharmacological interventions for opioid dependence.
Indeed, chronic opioid use and withdrawal symptoms have been associated with heightened 
aggression.9 Yet pharmacological interventions for opioid dependence consist of opioid 
agonists (e.g., methodone; buprenorphine), which bind to and activate endogenous opioid 
receptors to reduce the painful symptoms of opioid withdrawal, and opioid antagonists (e.g., 
naltrexone), which bind to but do not activate opioid receptors to reduce the rewarding 
euphoric effects associated with illicit opioid use.10 Thus, medications like methadone and 
Suboxone (i.e., a combination of buprenorphine and naloxone) should reduce the symptoms 
of irritability associated with opioid withdrawal among offenders receiving pharmacological 
treatment for opioid dependence. While reduced irritability and greater anger control are 
protective factors against aggressive behavioral responding, many risk factors have been 
identified for persistent partner violent behavior, including non-opioid substance use.11
A recent study of partner violent men receiving methadone treatment found that 62% of the 
sample demonstrated persistent substance use yet empirical data pertaining to the effects of 
comorbid substance use on IPV among individuals with opioid dependence remain limited, 
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particularly among female and offender samples.12 The most commonly abused substances 
within this population include cocaine, cannabis, and alcohol, all of which have been 
associated with poorer outcomes and relapse rates throughout and following treatment for 
opioid dependence.13 Among clinical and community samples, problematic alcohol and 
cocaine use are independently associated with greater frequency and severity of IPV 
perpetration among males and females whereas cannabis and IPV appear to share a weaker 
or non-significant association.1,2,14,15 The relationships between partner violent behavior 
and alcohol as well as cocaine are often contextualized within direct effects etiological 
models which posit that proximal psychopharmacological effects of intoxication facilitate 
the restriction of attention to only the most salient (e.g., aggressive) cues and reduce 
inhibitory control following exposure to aversive stimuli.16 Evidence pertaining to the direct 
effects of cannabis use on partner aggression is mixed, though disproportionately suggests 
that cannabis does not proximally increase the risk of IPV perpetration.17
It remains unclear if comorbid non-opioid substance use may explain some of the variability 
in IPV perpetration observed across studies of opioid dependent samples or the degree to 
which specific substances may differentially represent risk factors for IPV perpetration. The 
current study is the first to identify the prevalence of comorbid IPV, alcohol, cannabis, 
cocaine, and benzodiazepine use among a sample of male and female offenders receiving 
pharmacological treatment for opioid dependence. Analyses were undertaken to provide 
initial insight into variability in IPV perpetration among this unique subset of offenders. 
Consistent with previous research, we hypothesized that (1) participants who reported any 
comorbid substance use disorder, as an indicator of substance use severity, would be more 
likely to report IPV perpetration than participants with only an opioid use disorder. We then 
hypothesized that (2) participants with comorbid alcohol or cocaine use disorders would be 
more likely to report IPV than participants without comorbid use. Finally, we hypothesized 
that (3) cannabis would not be associated with reports of IPV among the current sample. 
Due to limited empirical guidance, we evaluated but offered no a priori hypotheses about the 
association between IPV and benzodiazepine use or the effects of gender on the associations 
among IPV and specific substances.
 Method
 Sample
Data collected on 1,926 offenders from a larger program-evaluation investigation were 
examined for inclusion and exclusion criteria in the current study. Specifically, the larger 
investigation assessed biopsychosocial correlates and outcomes of substance use among 
general criminal offenders suspected of substance abuse or dependence during the 
commission of criminal activities.18 Participants were considered eligible for inclusion in 
the present analyses if they reported the current use of a single medication designated to 
treat opioid dependence (e.g., methadone; buprenorphine), received an opioid use diagnosis, 
and provided complete substance use and IPV perpetration data during the initial data 
collection phase of the larger investigation. Ninety-one participants reported use of a 
pharmacological agent used to treat opioid dependence. Three of these individuals reported 
naltrexone use and had not been diagnosed with an opioid use disorder. Seven participants 
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receiving pharmacological intervention for opioid dependence refused to provide data 
pertaining to IPV perpetration, resulting in a final sample of 81 (55 male) participants. 
Sample characteristics are displayed in Table 1.
 Procedure
The procedure used in the current study is detailed elsewhere.18 Briefly, offenders opted to 
participate in a single-session, presentencing substance use evaluation to determine potential 
treatment needs and the degree to which substance use may have mitigated their culpability 
for criminal offenses. The comprehensive, two-hour clinical interviews were conducted by 
an experienced licensed clinical social worker (LCSW) with specialty training in substance 
use evaluation and treatment. The interviews began with a description of the limits of 
confidentiality and the completion of consent procedures. Interviewers made use of 
structured and open ended assessments as well as available collateral contacts, treatment 
information, court documents, and toxicology results to confirm offender reports. The 
interviewer recorded demographic, IPV, prescription, and substance use data for later 
analyses. Data used in the current study were collected at a single site in New Haven, 
Connecticut, de-identified, and retained for the purposes of program evaluation. The Human 
Investigation Committee (HIC) at the Yale University School of Medicine approved a 
request to conduct the study.
 Measures
Socio-demographic data, including participant age, ethnicity, and education history were 
provided by participants in response to structured interview questions. Participants also 
provided a list of current medications and documentation, when possible, that was used to 
determine involvement in opioid treatment. Interviewers reached substance use diagnoses 
based upon verbal responses to an adapted version of the psychometrically sound substance 
abuse section of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID).19 
For the purposes of the current investigation, abuse and dependence diagnoses were 
collapsed to produce dichotomous variables depicting the presence or absence of a current 
comorbid alcohol, cannabis, cocaine, or benzodiazepine-related “substance use disorder.” 
Immediately prior to the section of the interview inquiring about IPV, participants were 
informed by the interviewer that responses to IPV questions were entirely voluntary, would 
be used only in composite analyses, and would not be included in any official 
correspondence with the court. In compliance with requests from the agency conducting 
substance use evaluations, IPV assessments were kept brief. Participants were 
dichotomously categorized by the interviewer as partner violent or nonviolent based upon 
their verbal responses to an open-ended IPV screening question (i.e., “Have you been 
physically aggressive toward a romantic partner during the previous year?”).20
 Data analytic plan
Analyses involved preliminary exploration of the data, followed by the use of chi-square 
analyses to assess bivariate relationships among reported IPV and current, comorbid 
substance use diagnoses. A binomial logistic regression analysis was then conducted to 
assess relative strengths of substance use predictors as well as gender effects. With youth 
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and low socioeconomic status functioning as documented risk factors for a wide range of 
externalizing behaviors, analyses control for age and years of education.21
 Results
 Preliminary analyses
Demographic, violence, pharmacological treatment, and comorbid substance use disorder 
data are presented in Table 1. Analyses were conducted to determine the association between 
specific opioid medications and self-reported IPV as well as comorbid substance use in the 
current sample. Preliminary results indicated that rates of IPV were comparable among 
offenders prescribed methadone [0 = all other medications, 1 = methadone only: χ2(1) = .71, 
p = .40, d = 0.24] or Suboxone [0 = all other medications, 1 = Suboxone only: χ2(1) = 0.61, 
p = .43, d = -0.25]. Analyses further revealed that offenders prescribed methadone were less 
likely to report a current cannabis use disorder [χ2(1) = 5.75, p = .02, d = -0.64] whereas 
offenders prescribed Suboxone were less likely to report a current cocaine use disorder 
[χ2(1) = 4.67, p = .03, d = -0.62] relative to offenders not prescribed the respective 
medication. Meaningful analyses could not be conducted among the small subsample of 
offenders prescribed only buprenorphine or naltrexone. While it is possible that participants 
who reported using only buprenorphine were, in fact, prescribed Suboxone, there are several 
clinical contraindications for naloxone that would justify a buprenorphine-only prescription.
 Substance use and IPV
Our first hypothesis, that participants who reported any comorbid substance use disorder 
would be more likely to report IPV perpetration than participants with only an opioid use 
disorder, was not supported by the data. Analyses revealed that having a current comorbid 
substance use disorder shared an effect size of medium magnitude but was not significantly 
associated with reported IPV among offenders receiving treatment for opioid dependence 
[χ2(1) = 2.27, p = .13, d = .64]. Results suggest a need to examine the relationships between 
IPV data and specific substance use disorders, rather than the composite categorization 
which may obscure important associations.
Similar analyses were applied to each specific substance use disorder to evaluate our second 
hypothesis, that participants with comorbid alcohol or cocaine use disorders would be more 
likely to report IPV than participants without comorbid use, as well as our third hypothesis, 
that cannabis use diagnoses would not be associated with reported IPV. Cocaine shared a 
large effect size and was significantly as well as positively associated with IPV [χ2(1) = 
9.32, p < .01, d = .96]. Benzodiazepine use shared a similar association with IPV [χ2(1) = 
6.58, p = .01, d = .81]. Alcohol [χ2(1) = 0.33, p = .57, d = -.22] and cannabis [χ2(1) = 1.58, p 
= .21, d = -.35] use were not associated with an increased risk of reporting IPV. Together, 
results from bivariate analyses of partner violence and individual substances indicate that 
participants with comorbid cocaine or benzodiazepine, but not alcohol or cannabis, use 
disorders were significantly more likely to report perpetrating acts of IPV than their 
counterparts who reported no use of the respective substance.
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Probing the IPV-substance use relationship further, a logistic regression revealed that 
bivariate relationships remained in a composite model after controlling for age and 
education with significant main effects for current comorbid cocaine and benzodiazepine, 
but not alcohol or cannabis, use diagnoses in the prediction of reported IPV perpetration. A 
main effect emerged for gender, indicating that female participants were more likely to 
report IPV perpetration than male participants in the current sample. No gender-substance 
use interactions reached significance, indicating that associations between reported IPV and 
specific substances were comparable among male and female offenders. As interactions 
were non-significant, they were not included in the final model (see Table 2).
 Discussion
The current study offers initial insight into substance use factors that may partially account 
for increased risk of IPV perpetration among individuals receiving pharmacotherapy for 
opioid dependence. Specifically, we found that current diagnoses of comorbid cocaine and 
benzodiazepine use were associated with a greater likelihood of reporting IPV perpetration. 
Thus, in addition to being particularly dangerous substances to abuse while taking 
medications that contain opioid agonists, such as methadone and Suboxone, cocaine and 
benzodiazepine use are also indicators of physical risk for relationship partners. Although 
the methodology utilized in the current study expressly precludes the ability to infer 
causality, this investigation is among the first to find support, at the correlational level, for 
models positing that comorbid substance use increases the risk of violence among 
individuals receiving pharmacotherapy for opioid dependence through direct, proximal 
effects. Alternatively, however, the observed relationships may be spurious with a third 
variable, such as antisocial traits, contributing to increased externalizing behavior across 
both substance use and violence domains. Participants in the current study were all 
offenders, suggesting that antisocial features were likely elevated in comparison to the 
general population.22 Future studies with a more variable subject pool may be able to 
determine the role of potential third variables.
Unexpectedly, and contrary to both theory as well as the wider literature,23 comorbid alcohol 
use disorders were not associated with reports of IPV perpetration among offenders in the 
current study. This may be partially attributed to the fact that the current sample was 
unconventional in substance use history, such that alcohol was not the principle drug of 
choice. Consistent with prior research, however, cannabis use was not found to be a risk 
factor for IPV and female offenders were more likely to self-report IPV perpetration than 
male offenders. It should be noted that perpetration was assessed indiscriminate of 
motivation and violence severity. While evidence suggests that females perpetrate more 
frequent acts of IPV, males seem to be disproportionately responsible for acts of severe 
violence.24
 Limitations
Although the preliminary analyses reported here are the first to examine the relationships 
between comorbid substance use disorders and IPV in a clinical sample receiving 
pharmacotherapy for opioid dependence, the current study is not without limitations. Our 
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sample was homogeneous in ethnicity and relatively small, which must be acknowledged in 
cautiously interpreting the absence of significant gender interactions. For practical reasons, a 
brief physical IPV assessment was conducted. Brief, self-report IPV screening instruments 
similar to the one used in the current study, have demonstrated reliability and have received 
empirical support.25 This method does, however, leave room for subjective interpretation. 
We recommend that future investigations conduct a more nuanced assessment of comorbid 
substance use effects on IPV among offenders receiving pharmacotherapy for opioid 
dependence by evaluating distinctions in violence perpetration, including the use of specific 
minor and severe forms of physical, psychological, and sexual IPV. Finally, data were 
primarily provided by participant self-report, which introduces the potential for inaccuracy 
in substance use, treatment, and IPV history. It is unlikely that offenders would be motivated 
to falsely deny potentially mitigating factors, such as substance use, at the presentencing 
phase of the trial.
We encourage additional research in the area of general aggression to replicate the observed 
associations between specific substances of abuse and partner violent behavior among 
individuals receiving pharmacotherapy for opioid dependence. With a subset of partner 
violence perpetrators being reliably classified as generally-violent / antisocial, 
indiscriminately perpetrating acts of violence against others,26 future investigations that 
collect data on the duration of opioid treatment to assess the temporal sequencing of illicit 
substance use, opioid treatment, and violent behavior directed toward intimate partners and 
non-partners may be critical in establishing causal relationships, assessing the 
generalizability of the observed effects, and establishing indicators for elevated aggressive 
potential among treatment seekers.
 Conclusions
The current results offer further support for the ongoing need to conduct routine partner 
violence screenings among substance involved offenders. Findings also highlight a potential 
need to develop individualized treatment plans that may include supportive interventions for 
concurrent cocaine and benzodiazepine use disorders or integrated substance abuse and 
partner violence protocols to reduce the risk of IPV among relationally involved patients 
receiving pharmacotherapy for opioid dependence.
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